Polaris Group announced the submission to TFDA of phase 2a clinical protocol treating non-Alcohol steatohepatitis (NASH) with ADI-PEG 20, a first-in-class arginine deprivation therapy. The trial is designed as a randomized, double-blind, multi-center study for the treatment of NASH.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
72 TWD | +0.98% | +5.26% | -4.76% |
05-15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
05-14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 1.65B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Announces Submission of Phase 2a Clinical Protocol Treating NASH to TFDA